Definitive Healthcare (NASDAQ:DH) Updates FY24 Earnings Guidance

Definitive Healthcare (NASDAQ:DH) issued an update on its FY24 earnings guidance on Tuesday morning. The company provided earnings per share guidance of $0.32-0.34 for the period, compared to the consensus earnings per share estimate of $0.37. The company issued revenue guidance of $247-251 million, compared to the consensus revenue estimate of $258.33 million. Definitive Healthcare also updated its FY 2024 guidance to 0.320-0.340 EPS.

Definitive Healthcare Stock Down 3.9 %

Shares of NASDAQ DH traded down $0.23 during trading hours on Tuesday, hitting $5.74. The company had a trading volume of 3,696,056 shares, compared to its average volume of 710,079. The stock has a market capitalization of $676.92 million, a P/E ratio of -3.28, a price-to-earnings-growth ratio of 4.36 and a beta of 1.30. The company has a quick ratio of 2.30, a current ratio of 2.30 and a debt-to-equity ratio of 0.20. Definitive Healthcare has a 1-year low of $4.38 and a 1-year high of $11.97. The firm’s 50 day moving average is $5.55 and its 200-day moving average is $7.17.

Definitive Healthcare (NASDAQ:DH) last released its quarterly earnings data on Tuesday, May 7th. The company reported ($0.02) EPS for the quarter, missing the consensus estimate of $0.02 by ($0.04). The company had revenue of $63.48 million during the quarter, compared to analyst estimates of $64.00 million. Definitive Healthcare had a negative net margin of 78.16% and a positive return on equity of 0.51%. On average, analysts expect that Definitive Healthcare will post 0.1 earnings per share for the current fiscal year.

Analyst Ratings Changes

DH has been the subject of several research reports. Needham & Company LLC reaffirmed a hold rating on shares of Definitive Healthcare in a report on Wednesday, May 8th. Deutsche Bank Aktiengesellschaft decreased their price target on Definitive Healthcare from $10.00 to $7.00 and set a hold rating on the stock in a research report on Thursday, May 9th. Canaccord Genuity Group cut their price target on Definitive Healthcare from $10.00 to $8.00 and set a hold rating on the stock in a research note on Wednesday, May 8th. Barclays cut their price target on Definitive Healthcare from $11.00 to $7.00 and set an equal weight rating on the stock in a research note on Thursday, May 9th. Finally, Stifel Nicolaus cut their price target on Definitive Healthcare from $11.00 to $9.50 and set a buy rating on the stock in a research note on Wednesday, May 8th. Eight analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. Based on data from MarketBeat, the company has an average rating of Hold and a consensus target price of $9.56.

Definitive Healthcare Company Profile

Definitive Healthcare Corp., together with its subsidiaries, provides software as a service (SaaS) healthcare commercial intelligence platform in the United States and internationally. Its SaaS platform provides information on healthcare providers and their activities to help its customers from product development to go-to-market planning, and sales and marketing execution.